F
Farideh Alasti
Researcher at Medical University of Vienna
Publications - 38
Citations - 1063
Farideh Alasti is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Rheumatoid factor. The author has an hindex of 15, co-authored 35 publications receiving 780 citations.
Papers
More filters
Journal ArticleDOI
Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
TL;DR: The DAPSA constitutes a disease-specific, validated and feasible tool for PsA assessment and provides criteria for disease activity states and treatment response, based on an international expert survey.
Journal ArticleDOI
Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity.
TL;DR: The data reveal that damage progression in seropositive RA patients is related to higher levels of disease activity and to independent effects of RF, particularly on bone damage.
Journal ArticleDOI
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
TL;DR: The data presented suggest that the presence of RF has a clear association with higher levels of disease activity but that the existence of ACPAs has not and even appears to be associated with lower disease activity.
Journal ArticleDOI
Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression
TL;DR: Higher DAPSA scores were significantly and independently associated with probability of structural progression in multiple analyses, and highly valid for future use as endpoints in clinical trials or as targets in clinical practice.
Journal ArticleDOI
Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point
TL;DR: Not achieving minor responses at 3’months makes reaching of the treatment target at 6 months highly unlikely, while reaching major responses is highly predictive of reaching the treatment targets.